Gri bio reports first quarter 2025 financial results and confirms gri-0621 phase 2a ipf trial on track for 6-week interim data in q2 2025 and topline data in q3 2025

Positive interim 2-week safety and biomarker results from its ongoing phase 2a study evaluating gri-0621 for the treatment of idiopathic pulmonary fibrosis (“ipf”)

GRI Ratings Summary

GRI Quant Ranking